140 related articles for article (PubMed ID: 24668646)
1. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
3. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
Sperinde J; Huang W; Vehtari A; Chenna A; Kellokumpu-Lehtinen PL; Winslow J; Bono P; Lie YS; Petropoulos CJ; Weidler J; Joensuu H
Clin Cancer Res; 2018 Jul; 24(13):3046-3052. PubMed ID: 29535130
[No Abstract] [Full Text] [Related]
4. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
[TBL] [Abstract][Full Text] [Related]
5. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
6. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
7. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
8. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
9. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
[TBL] [Abstract][Full Text] [Related]
10. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
[TBL] [Abstract][Full Text] [Related]
11. p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?
Kocar M; Bozkurtlar E; Telli F; Yumuk F; Kaya H; Kocar H; Serdar Turhal N
J BUON; 2014; 19(1):245-9. PubMed ID: 24659671
[TBL] [Abstract][Full Text] [Related]
12. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
Duchnowska R; Sperinde J; Chenna A; Huang W; Weidler JM; Winslow J; Haddad M; Paquet A; Lie Y; Trojanowski T; Mandat T; Kowalczyk A; Czartoryska-Arłukowicz B; Radecka B; Jarosz B; Staszkiewicz R; Kalinka-Warzocha E; Chudzik M; Biernat W; Jassem J
Neuro Oncol; 2015 Sep; 17(9):1241-9. PubMed ID: 25681308
[TBL] [Abstract][Full Text] [Related]
13. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
14. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
[TBL] [Abstract][Full Text] [Related]
16. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
17. P95 HER2 fragments and breast cancer outcome.
Tural D; Akar E; Mutlu H; Kilickap S
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
[TBL] [Abstract][Full Text] [Related]
18. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
20. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]